The Pomi-T trial was first announced to the World at the 2013 American Society of Clinical Oncology Conference (ASCO). It was presented in the main plenary session on prostate cancer – An enormous privilege for the research team as these are reserved for the best and most significant studies, internationally for the previous year. ASCO is the largest and most most prestigious medical conference each year so not surprisingly there was a substantial interest from the Media in Newspapers, website, radio, podcasts and TV. Here are just a few examples of the media coverage: